2001
DOI: 10.1080/14764170160260762
|View full text |Cite
|
Sign up to set email alerts
|

Intracutaneous botulinum toxin A versus ablative therapy of Hailey-Hailey disease - a case report

Abstract: BTXA is capable of inducing remissions of Hailey-Hailey disease without abrasion for at least 12 months. Among ablative treatments, erbium: YAG laser therapy leads to a more rapid wound closure than dermabrasion, with both causing complete remissions.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
43
1
1

Year Published

2004
2004
2024
2024

Publication Types

Select...
5
5

Relationship

1
9

Authors

Journals

citations
Cited by 54 publications
(47 citation statements)
references
References 12 publications
2
43
1
1
Order By: Relevance
“…There is a wide range of benign tumors, cysts or hyperkeratotic disorders that have been successfully treated or at least alleviated by erbium-YAG laser application such as nevus sebaceous, actinic porokeratosis, osteoma cutis or angiokeratoma [25][26][27][28][29].…”
Section: Discussionmentioning
confidence: 99%
“…There is a wide range of benign tumors, cysts or hyperkeratotic disorders that have been successfully treated or at least alleviated by erbium-YAG laser application such as nevus sebaceous, actinic porokeratosis, osteoma cutis or angiokeratoma [25][26][27][28][29].…”
Section: Discussionmentioning
confidence: 99%
“…[23][24][25][26][27][28][29][30][31][32][33] Botulinum toxin (axillary or inframammary) may help by reducing sweating, as may breast reduction. [34][35][36] Although ultraviolet light may exacerbate Hailey-Hailey disease, PUVA was apparently effective in some patients. Suberythemal UVB controlled both psoriasis and co-existing Hailey-Hailey disease in another patient.…”
Section: Treatmentmentioning
confidence: 99%
“…Indications not approved by FDA, but studied and reported in the medical literature, include extracervical spasticities, 8,9 especially for patients with cerebral palsy, [10][11][12][13][14][15][16] poststroke spasticity, 17,18 and piriformis syndrome. 19,20 Other reports describe off-label uses for a wide range of neurologic, [21][22][23][24][25][26] dermatologic, [27][28][29][30][31][32] gastrointestinal, [33][34][35][36][37][38][39][40][41][42] and other clinical [43][44][45][46][47][48][49][50][51] disorders, often without controlled clinical trials. Off-label use of a licensed drug or biologic product occurs with a wide range of products.…”
mentioning
confidence: 99%